Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery
The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery.
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
BALA CYNWYD, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Medical device company Globus Medical (NYSEGMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.6% year on year to $657.3 million. The company expects the full year’s revenue to be around $2.68 billion, close to analysts’ estimates. Its non-GAAP profit of $0.84 per share was 12.2% above analysts’ consensus estimates.
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024.
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSEGMED), a leading musculoskeletal solutions company, and Nevro Corp. NYSE: NVRONYSENVRO)
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.
